The dose-ranging trial, which is being conducted in Germany, will enroll 48 volunteers and will involve the testing of three different doses over 20 days. Completion of the trial is expected before the end of December 2005.
“We believe Anturol for overactive bladder syndrome represents a competitive opportunity in a large and growing market segment,” commented Dr Dario Carrara, managing director of Antares’ pharmaceutical and formulation division in Switzerland. “In particular, we believe that our product offers increased efficacy and fewer side-effects than existing products in this category.”
Overactive bladder syndrome affects an estimated 17 million people in the US, with the highest incidence of occurrence in women of post-menopausal age.